Choe Seon, Jerng Ui Min, Park Jeong Hwan, Kim Sungha, Kim Sungchul, Lee Jinbok, Lee Jun-Hwan, Shin Minseop
Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea.
Clinical Medicine Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.
J Pharmacopuncture. 2020 Dec 31;23(4):247-251. doi: 10.3831/KPI.2020.23.4.251.
Ganglion cysts require a sustainable treatment that suppresses their frequent recurrence. This study aimed to explore the clinical effects of pharmacopuncture (SP) and electroacupuncture on ganglion cysts.
We retrospectively reviewed the patient records and follow-up reports for 20 patients with wrist ganglion cysts who received SP and electroacupuncture from April 2016 to March 2017. The cyst diameter, recurrence, visual analog scale (VAS) scores for pain, the Korean version of the disabilities of arm, shoulder, and hand (K-DASH) score, and the Korean version of the patient-rated wrist evaluation (K-PRWE) score before and after treatment were noted.
After treatment, the cyst diameter decreased significantly from 13.61 ± 6.41 mm to 5.15 ± 6.18 mm (p < 0.001), and VAS score for pain decreased from 1.31 ± 1.77 to 0.41 ± 0.33 (p = 0.021). Further, the K-DASH score decreased significantly from 8.97 ± 12.66 to 2.21 ± 7.39 (p = 0.016), and score for the function subscale of K-PRWE decreased from 11.37 ± 4.48 to 9.1 ± 3.67 (p = 0.046). No recurrences were reported from the followed-up patients. Any complication related to SP or electroacupuncture was not observed, except mild rash, itching, and swelling at the injection site in four patients.
Combination of SP and electroacupuncture may be effective in treating ganglion cysts; further prospective studies with large population are needed to clarify the effect of SP and electroacupuncture.
腱鞘囊肿需要一种能抑制其频繁复发的可持续治疗方法。本研究旨在探讨药物穴位注射(SP)和电针治疗腱鞘囊肿的临床效果。
我们回顾性分析了2016年4月至2017年3月期间接受SP和电针治疗的20例腕部腱鞘囊肿患者的病历和随访报告。记录治疗前后囊肿直径、复发情况、疼痛视觉模拟量表(VAS)评分、韩国版上肢、肩部和手部功能障碍(K-DASH)评分以及韩国版患者自评腕关节评估(K-PRWE)评分。
治疗后,囊肿直径从13.61±6.41mm显著减小至5.15±6.18mm(p<0.001),疼痛VAS评分从1.31±1.77降至0.41±0.33(p=0.021)。此外,K-DASH评分从8.97±12.66显著降至2.21±7.39(p=0.016),K-PRWE功能亚量表评分从11.37±4.48降至9.1±3.67(p=0.046)。随访患者均未报告复发情况。除4例患者注射部位出现轻度皮疹、瘙痒和肿胀外,未观察到与SP或电针相关的任何并发症。
SP和电针联合治疗腱鞘囊肿可能有效;需要进一步开展大样本前瞻性研究以明确SP和电针的疗效。